Johnson & Johnson/$JNJ

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

Ticker

$JNJ
Sector

Primary listing

NYSE

Employees

138,100

JNJ Metrics

BasicAdvanced
$426B
18.96
$9.33
0.40
$5.08
2.94%

What the Analysts think about JNJ

Analyst ratings (Buy, Hold, Sell) for Johnson & Johnson stock.

Bulls say / Bears say

Johnson & Johnson’s Q2 2025 adjusted EPS of $2.77 and revenue of $23.74 billion both exceeded analyst forecasts, prompting management to raise full-year sales guidance to $93.2–93.6 billion and adjusted EPS to $10.80–10.90 (Reuters)
Sales of cancer drug Darzalex reached $3.54 billion in Q2 2025—4% ahead of estimates—demonstrating the drug’s sustained market leadership and strengthening J&J’s oncology business (Reuters)
The FDA’s April 30 approval of IMAAVY™ for generalized myasthenia gravis opens a new immunology market with high unmet need, with peak sales expected to surpass $5 billion, further diversifying J&J’s innovative medicine portfolio (Reuters)
A U.S. bankruptcy judge’s April 1 rejection of Johnson & Johnson’s $10 billion talc settlement leaves over 60,000 ovarian cancer and mesothelioma claims unresolved, exposing the company to potential multi-billion dollar jury awards and lengthy litigation costs (Reuters)
Kenvue, J&J’s 2023 consumer-health spin-off, has forecast 2025 profit below Wall Street expectations and faces pressure from activist investors over its underperforming skin-health and beauty divisions, highlighting risks in J&J's decision to divest its stabilizing consumer business (FT)
Proposed U.S. pharmaceutical import tariffs, potentially reaching as high as 250%, prompted J&J’s $2 billion investment in U.S. manufacturing, emphasizing a significant risk to drug profit margins if these duties go into effect (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 28 Aug 2025.

JNJ Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

JNJ Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $JNJ

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs